Archive
Browse market commentary, macro analysis, and student-led reporting.
3 articles tagged Biotechnology Clear tag
MarketsGlobal Healthcare2 August 2026
Big Pharma is acquiring earlier and accepting greater scientific risk for unproven drugs. The driver is not confidence in the science but the fear of a rival securing the next blockbuster first, as a $300bn patent cliff bears down on the industry.
PharmaceuticalsMergers and AcquisitionsBiotechnologyPatent Cliff
Abdul Wasey Bhatti8 min read
Read ArticleMarketsGlobal Healthcare10 July 2026
Vertex's $10 billion acquisition of Crinetics is about far more than adding another drug to its portfolio. It is a strategic bet on an endocrinology platform that could fuel the company's next phase of growth.
Vertex PharmaceuticalsCrinetics PharmaceuticalsBiotechnologyMergers and Acquisitions
Abdul Wasey Bhatti6 min read
Read ArticleMarketsGlobal Healthcare26 June 2026
A single FDA reversal sent Regenxbio's shares soaring and reignited optimism across gene therapy - but one favourable decision cannot solve the commercial challenges that pushed the industry into crisis.
Gene TherapyBiotechnologyFDAHealthcare
Abdul Wasey Bhatti6 min read
Read Article